Outlook Therapeutics (OTLK) Proxy filing summary

Executive summary

• Supplemental proxy materials update shareholders on Nasdaq listing compliance and proxy solicitation details.

• The company regained compliance with Nasdaq's minimum bid price rule as of June 25, 2026, after previously facing delisting risk.

• Ongoing compliance with Nasdaq listing standards remains critical for liquidity and capital market access.

Voting matters and shareholder proposals

• Proposal No. 3 seeks approval for a potential reverse stock split to help maintain Nasdaq listing requirements.

• If a reverse stock split is not implemented within one year, new shareholder approval will be required before any future split.

Shareholder rights and capital structure

• Maintaining a minimum bid price is essential to avoid delisting and protect shareholder value.

• Reverse stock split authorization is positioned as a tool to support continued listing and capital market access.